BRPI1015367A2 - imidazotiodiazois para uso como inibidores de cinase - Google Patents

imidazotiodiazois para uso como inibidores de cinase

Info

Publication number: BRPI1015367A2
Authority: BR; Brazil
Prior art keywords: imidazotiodiazoles; kinase inhibitors; kinase; inhibitors
Prior art date: 2009-04-02

Application number

BRPI1015367A

Other languages

English (en)

Inventor

Kurz Guido

Pastor Fernández Joaquín

Martínez Gonzales Sonia

Original Assignee

Centro Nac De Investigaciones Oncologicas Cnio

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-02

Filing date

2010-04-01

Publication date

2018-02-20

2010-04-01 Application filed by Centro Nac De Investigaciones Oncologicas Cnio filed Critical Centro Nac De Investigaciones Oncologicas Cnio

2018-02-20 Publication of BRPI1015367A2 publication Critical patent/BRPI1015367A2/pt

2021-05-11 Publication of BRPI1015367B1 publication Critical patent/BRPI1015367B1/pt

2021-05-25 Publication of BRPI1015367B8 publication Critical patent/BRPI1015367B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Oncology (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)

BRPI1015367A 2009-04-02 2010-04-01 derivados imidazo[2,1-b][1,3,4]tiadiazol BRPI1015367B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09380069		2009-04-02
EP09380069.6		2009-04-02
PCT/GB2010/000674 WO2010112874A1 (en)	2009-04-02	2010-04-01	Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives

Publications (3)

Publication Number	Publication Date
BRPI1015367A2 true BRPI1015367A2 (pt)	2018-02-20
BRPI1015367B1 BRPI1015367B1 (pt)	2021-05-11
BRPI1015367B8 BRPI1015367B8 (pt)	2021-05-25

Family

ID=40750794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1015367A BRPI1015367B8 (pt)	2009-04-02	2010-04-01	derivados imidazo[2,1-b][1,3,4]tiadiazol

Country Status (23)

Country	Link
US (1)	US8815918B2 (pt)
EP (1)	EP2414369B1 (pt)
JP (1)	JP5615902B2 (pt)
KR (1)	KR101727264B1 (pt)
CN (1)	CN102388055B (pt)
AU (1)	AU2010231162B2 (pt)
BR (1)	BRPI1015367B8 (pt)
CA (1)	CA2756873C (pt)
CY (1)	CY1116880T1 (pt)
DK (1)	DK2414369T3 (pt)
EA (1)	EA022753B1 (pt)
ES (1)	ES2548571T3 (pt)
HR (1)	HRP20151126T1 (pt)
HU (1)	HUE027964T2 (pt)
IL (1)	IL215158A (pt)
MX (1)	MX2011010372A (pt)
NZ (1)	NZ595674A (pt)
PL (1)	PL2414369T3 (pt)
PT (1)	PT2414369E (pt)
SG (1)	SG175001A1 (pt)
SI (1)	SI2414369T1 (pt)
WO (1)	WO2010112874A1 (pt)
ZA (1)	ZA201107350B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0821913D0 (en)	2008-12-02	2009-01-07	Price & Co	Antibacterial compounds
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
GB2480815A (en) *	2010-06-01	2011-12-07	Summit Corp Plc	Compounds for the treatment of clostridium difficile-associated disease
PT2575968E (pt)	2010-06-01	2016-06-20	Summit Therapeutics Plc	Compostos para o tratamento de doença associada com clostridium difficile
WO2012020215A1 (en)	2010-08-09	2012-02-16	Centro Nacional De Investigaciones Oncológicas (Cnio)	Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020217A1 (en)	2010-08-09	2012-02-16	Centro Nacional De Investigaciones Oncológicas (Cnio)	Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
US20130196990A1 (en)	2010-10-06	2013-08-01	Junya Qu	Benzimidazole Derivatives As PI3 Kinase Inhibitors
TWI617559B (zh)	2010-12-22	2018-03-11	江蘇恆瑞醫藥股份有限公司	２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
AU2012257513B2 (en)	2011-05-19	2017-05-11	Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Macrocyclic compounds as protein kinase inhibitors
KR101399484B1 (ko)	2011-07-14	2014-05-29	한국화학연구원	허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
PT3186233T (pt)	2014-08-29	2021-12-02	Chdi Foundation Inc	Sondas para imagem de proteína de huntingtina
BR112017004134A2 (pt) *	2014-08-29	2017-12-12	Chdi Foundation Inc	?sondas para imageamento de proteína de huntingtina?
MY200452A (en)	2018-08-21	2023-12-27	Kyorin Seiyaku Kk	Bicyclic heteroaromatic ring derivative
BR112021005082A2 (pt)	2018-09-18	2021-06-08	Nikang Therapeutics, Inc.	derivados de anel tricíclico fundido como inibidores de src homologia-2 fosfatase
EP4048678A4 (en)	2019-10-21	2023-10-18	Novartis AG	COMPOUNDS AND COMPOSITIONS FOR TREATING PARASITIC DISEASES
JP2023541262A (ja) *	2020-09-14	2023-09-29	ザユニバーシティーオブサセックス	Ｌｅｍｕｒチロシンキナーゼ３の小分子阻害剤

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1464259A (en)	1975-10-03	1977-02-09	Pfizer Ltd	Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US4444770A (en)	1980-05-29	1984-04-24	Bayer Aktiengesellschaft	New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (de)	1982-03-09	1983-09-15	Bayer Ag, 5090 Leverkusen	Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it)	1994-01-11	1997-03-21	Isagro Srl	Eterobicicli ad attivita' fungicida
AU7001396A (en)	1995-09-22	1997-04-09	Takeda Chemical Industries Ltd.	Triazole compounds, their production and use
JP2004505983A (ja) *	2000-08-09	2004-02-26	アグーロン　ファーマシューティカルズ，インコーポレイテッド	ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
CA2364985A1 (en) *	2001-12-14	2003-06-14	John W. Gillard	Imidazo(2,1-b)thiadiazole sulfonamides
KR101075812B1 (ko)	2002-12-18	2011-10-25	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서의 트리아졸로피리다진
PA8595001A1 (es)	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
KR20060017645A (ko)	2003-06-13	2006-02-24	에게라 쎄라퓨틱스 인코포레이티드	아실화 및 비-아실화 이미다조[2,1-ｂ]-1, 3,4-티아디아졸-2-설폰아미드, 및 그 용도
WO2004111060A1 (en) *	2003-06-13	2004-12-23	Aegera Therapeutics Inc.	IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
SE0402735D0 (sv)	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
WO2006128693A2 (en)	2005-06-01	2006-12-07	Ucb Pharma, S.A.	2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
US20070049591A1 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibitors of MAPK/Erk Kinase
US7750000B2 (en)	2005-09-02	2010-07-06	Bayer Schering Pharma Ag	Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
EP1963329B1 (en)	2005-11-30	2013-01-23	Vertex Pharmaceuticals Incorporated	Inhibitors of c-met and uses thereof
WO2007118318A1 (en)	2006-04-13	2007-10-25	Aegera Therapeutics Inc.	USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
EP2016075A1 (en)	2006-05-03	2009-01-21	AstraZeneca AB	Thiazole derivatives and their use as anti-tumour agents
WO2007136736A2 (en)	2006-05-19	2007-11-29	Codon Devices, Inc.	Methods for nucleic acid sorting and synthesis
CN101448827A (zh)	2006-05-22	2009-06-03	阿斯利康(瑞典)有限公司	吲哚衍生物
JP5336375B2 (ja)	2006-08-30	2013-11-06	セルゾームリミテッド	キナーゼ阻害剤としてのトリアゾール誘導体
US20110021513A1 (en)	2006-09-07	2011-01-27	Biogen Idec Ma Inc.	Modulators of interleukin-1 receptor-associated kinase
US7732468B2 (en)	2006-11-15	2010-06-08	Cytovia, Inc.	3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101037445A (zh)	2007-04-14	2007-09-19	西北师范大学	一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
WO2008138834A1 (en)	2007-05-09	2008-11-20	Novartis Ag	Substituted imidazopyridazines as pi3k lipid kinase inhibitors
PE20090717A1 (es)	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
US20090156594A1 (en) *	2007-05-21	2009-06-18	Sgx Pharmaceuticals, Inc.	Heterocyclic kinase modulators
US8481572B2 (en) *	2007-08-09	2013-07-09	Urifer Ltd.	Pharmaceutical compositions and methods for the treatment of cancer
HUE025976T2 (en)	2007-09-27	2016-05-30	Fund Centro Nac De Investig Oncologicas Carlos Iii	Imidazolothiadiazoles for use as protein kinase inhibitors
EP2211615A4 (en)	2007-10-22	2010-10-13	Glaxosmithkline Llc	PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2307425B1 (en)	2008-07-29	2014-03-26	Merck Patent GmbH	Imidazothiadiazoles derivatives

2010
- 2010-04-01 SG SG2011071412A patent/SG175001A1/en unknown
- 2010-04-01 HR HRP20151126TT patent/HRP20151126T1/hr unknown
- 2010-04-01 PL PL10715318T patent/PL2414369T3/pl unknown
- 2010-04-01 US US13/262,183 patent/US8815918B2/en active Active
- 2010-04-01 CA CA2756873A patent/CA2756873C/en active Active
- 2010-04-01 EP EP10715318.1A patent/EP2414369B1/en active Active
- 2010-04-01 EA EA201101435A patent/EA022753B1/ru not_active IP Right Cessation
- 2010-04-01 JP JP2012502778A patent/JP5615902B2/ja not_active Expired - Fee Related
- 2010-04-01 MX MX2011010372A patent/MX2011010372A/es active IP Right Grant
- 2010-04-01 AU AU2010231162A patent/AU2010231162B2/en not_active Ceased
- 2010-04-01 PT PT107153181T patent/PT2414369E/pt unknown
- 2010-04-01 CN CN201080015246.6A patent/CN102388055B/zh not_active Expired - Fee Related
- 2010-04-01 NZ NZ595674A patent/NZ595674A/xx not_active IP Right Cessation
- 2010-04-01 ES ES10715318.1T patent/ES2548571T3/es active Active
- 2010-04-01 KR KR1020117026103A patent/KR101727264B1/ko not_active Expired - Fee Related
- 2010-04-01 DK DK10715318.1T patent/DK2414369T3/en active
- 2010-04-01 HU HUE10715318A patent/HUE027964T2/en unknown
- 2010-04-01 WO PCT/GB2010/000674 patent/WO2010112874A1/en not_active Ceased
- 2010-04-01 BR BRPI1015367A patent/BRPI1015367B8/pt not_active IP Right Cessation
- 2010-04-01 SI SI201031054T patent/SI2414369T1/sl unknown
2011
- 2011-09-15 IL IL215158A patent/IL215158A/en active IP Right Grant
- 2011-10-07 ZA ZA2011/07350A patent/ZA201107350B/en unknown
2015
- 2015-11-03 CY CY20151100981T patent/CY1116880T1/el unknown

Also Published As

Publication number	Publication date
KR101727264B1 (ko)	2017-04-14
NZ595674A (en)	2012-12-21
ZA201107350B (en)	2015-06-24
BRPI1015367B1 (pt)	2021-05-11
JP2012522759A (ja)	2012-09-27
EP2414369A1 (en)	2012-02-08
PL2414369T3 (pl)	2016-04-29
SI2414369T1 (sl)	2015-12-31
CN102388055B (zh)	2015-07-29
US20120094996A1 (en)	2012-04-19
WO2010112874A1 (en)	2010-10-07
IL215158A (en)	2015-07-30
SG175001A1 (en)	2011-11-28
KR20120034607A (ko)	2012-04-12
AU2010231162A1 (en)	2011-11-03
CY1116880T1 (el)	2017-04-05
CN102388055A (zh)	2012-03-21
EA022753B1 (ru)	2016-02-29
CA2756873A1 (en)	2010-10-07
MX2011010372A (es)	2012-01-12
CA2756873C (en)	2018-01-09
JP5615902B2 (ja)	2014-10-29
IL215158A0 (en)	2011-12-29
HUE027964T2 (en)	2016-11-28
DK2414369T3 (en)	2015-09-21
US8815918B2 (en)	2014-08-26
HRP20151126T1 (hr)	2015-11-20
BRPI1015367B8 (pt)	2021-05-25
ES2548571T3 (es)	2015-10-19
HK1166979A1 (zh)	2012-11-16
EA201101435A1 (ru)	2012-04-30
PT2414369E (pt)	2015-10-22
AU2010231162B2 (en)	2014-12-11
EP2414369B1 (en)	2015-08-12

Publication	Publication Date	Title
BRPI1014572A2 (pt)	2016-04-26	imidazoprazinas para uso como inibidores de cinase
FR25C1006I1 (fr)	2025-04-04	Inhibiteurs de pyrazolyl-quinoxaline kinase
BRPI1015367A2 (pt)	2018-02-20	imidazotiodiazois para uso como inibidores de cinase
BRPI1014708A2 (pt)	2016-04-12	dihidropirimidinonas para uso como inibidores de bace2
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
DK2414362T3 (da)	2014-09-22	Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
CO6880065A2 (es)	2014-02-28	Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
EP2498607A4 (en)	2013-06-19	Kinase Inhibitors
EP2493313A4 (en)	2013-05-15	Kinase Inhibitors
BR112013004025A2 (pt)	2016-06-28	amarra para uso hortícola
DK2448938T3 (da)	2014-08-25	Pyrimidinoner som pi3k-inhibitorer
EP2710007A4 (en)	2015-04-01	Kinase inhibitors
CO6880068A2 (es)	2014-02-28	Aminoquinazolinas como inhibidores de quinasa
CO6970602A2 (es)	2014-06-13	Inhibidores de quinasa
BR112012029405A2 (pt)	2016-12-06	compostos macrocíclicos como inibidores de trk quinase
EP2558099A4 (en)	2013-07-17	Kinase inhibitors
BR112012002564A2 (pt)	2018-03-13	extensão de ue-rs para dwpts
BR112013016030A2 (pt)	2018-07-24	compostos e seu uso como inibidores de bace
BRPI0912475A8 (pt)	2018-03-20	compostos como inibidores de quinase
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
BRPI0910987A2 (pt)	2017-03-21	derivados de triazolopiridinona para uso como inibidores de estearoil-coa dessaturase
CO6862145A2 (es)	2014-02-10	Imidazopiridazinas como inhibidores de quinasa akt

Legal Events

Date	Code	Title	Description
2018-10-23	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-10-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-10-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-11-03	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2599 DE 27/10/2020 POR TER SIDO INDEVIDA.
2020-11-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-12-08	B25D	Requested change of name of applicant approved	Owner name: FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES)
2021-03-02	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-03-30	B09X	Republication of the decision to grant [chapter 9.1.3 patent gazette]
2021-05-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-01-23	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-05-14	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2768 DE 23-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.